



A SURESH G KARE Enterprise

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2009

(Rs. In Lacs)

Sr.No	Particulars	Quarter ended 31.12.2009 (Unaudited)	Quarter ended 31.12.2008 (Unaudited)	Nine Month Ended 31.12.2009 (Unaudited)	Nine Month Ended 31.12.2008 (Unaudited)	Year ended 31.03.2009 (Audited)
1	(a) Sales and Income from Operations	9,678	7,888	29,233	26,946	35,526
	Less : Excise Duty	108	96	286	343	462
	Net Sales and Income from Operations	9,570	7,792	28,947	26,603	35,064
	(b) Other Operating income	26	60	325	196	338
	Total	9,596	7,852	29,272	26,799	35,402
2	Expenditure :					
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	(186)	(441)	(260)	(857)	(513)
	(b) Consumption of raw materials	3,742	2,989	10,732	9,495	12,376
	(c) Purchase of traded goods	597	801	1,790	2,604	3,094
	(d) Employees cost	1,415	1,186	4,155	3,524	4,794
	(e) Depreciation	304	280	872	816	1,116
	(f) Research & Development Expenses	252	248	725	682	923
	(g) Other Expenditure	2,633	2,476	7,587	7,213	9,768
	(h) Total	8,757	7,539	25,601	23,477	31,558
3	Profit from Operations before Interest and Exceptional Items	839	313	3,671	3,322	3,844
4	Other Income	1	6	15	54	55
5	Profit before Interest and Exceptional Items	840	319	3,686	3,376	3,899
6	Interest	60	174	219	456	585
7	Profit after Interest but before Exceptional Items	780	145	3,467	2,920	3,314
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before tax	780	145	3,467	2,920	3,314
10	Provision for Tax - Current	133	12	587	321	370
	- Deferred	7	52	81	130	108
	- Fringe Benefit Tax	-	30	-	81	93
	- Prior Year	-	-	-	(31)	(31)
	- MAT Credit	(133)	(12)	(587)	(321)	(370)
11	Net Profit from Ordinary Activities after tax	773	63	3,386	2,740	3,144
12	Extraordinary Items	-	-	-	-	-
13	Net Profit for the period	773	63	3,386	2,740	3,144
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1,228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	-	26,616
16	Earning Per Share (EPS) - Not Annualised - Rs.					
	(a) Basic and diluted EPS before Extraordinary Items	6.29	0.51	27.56	22.30	25.59
	(b) Basic and diluted EPS after Extraordinary Items	6.29	0.51	27.56	22.30	25.59
17	Public shareholding					
	- No of Shares	47,89,936	48,74,541	47,89,936	48,74,541	50,29,231
	- % of Shareholding	38.98	39.67	38.98	39.67	40.93
18	Promoters and promoters group shareholding					
	a) Pledged/Encumbered					
	- Number of shares	8,200	-	8,200	-	8,200
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	-	0.11	-	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	-	0.07	-	0.07
	b) Non-encumbered					
	- Number of shares	74,88,578	-	74,88,578	-	72,49,283
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	-	99.89	-	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.95	-	60.95	-	59.00

Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.10.2009 : Nil, Received during quarter : 4, Resolved: 4, Pending as on 31.12.2009 : Nil.
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 27th January 2010 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai
Date : January 27, 2010

Suresh G. Kare
Chairman & Managing Director